Robert Califf addressed a range of issues, including AI, lack of nutrition resources at the FDA and how he evaluates the progress of precision medicine at the Precision Medicine World Conference in ...
The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback